Second-line chemotherapy for advanced hormone-refractory prostate cancer

Area of Science:

• Oncology
• Urology

Background:

• Prostate cancer is the most common cancer in US men, with approximately 30,000 developing incurable metastatic disease annually.
• While hormone therapies are initially effective, most patients develop androgen-independent progressive disease, known as hormone-refractory prostate cancer (HRPC).
• HRPC presents significant treatment challenges, as therapeutic options become limited after initial chemotherapy.

Purpose of the Study:

• To review all available Phase II and III clinical trial data for chemotherapy agents used in the second-line treatment of HRPC.
• To provide an overview of treatment efficacy and options for patients with advanced, refractory prostate cancer.

Main Methods:

• Systematic review of completed Phase II and III clinical trials.
• Analysis of data evaluating chemotherapy agents in the second-line HRPC setting.

Main Results:

• Three drugs (estramustine, mitoxantrone, docetaxel) are FDA-approved for first-line HRPC chemotherapy.
• Limited treatment options exist for patients progressing after first-line therapy, with less than half receiving second-line treatment.
• No therapies are currently FDA-approved for second-line HRPC, with only one Phase III trial completed in this setting.

Conclusions:

• There is a critical need for effective second-line chemotherapy options for patients with HRPC.
• Further clinical trials are essential to identify and validate new treatments for advanced prostate cancer.
• This review consolidates existing evidence to guide future research and clinical practice in HRPC management.